Medincell launches a Global Offer of 10% of its capital

On February 18, 2025, Medincell announced a Global Offering of approximately 10% of its share capital. This offer targets institutional investors via a Private Placement and individuals in France through PrimaryBid. The funds raised will enable Medincell to strengthen its financial structure and expand the application of its BEPO® technology to new molecules.

This initiative is in line with the company's objective to achieve operating profitability by 2027 and to quickly exceed €100 million in revenue. The launch of UZEDY and the development of a prolonged formulation of olanzapine demonstrate its ability to offer innovative treatments. Medincell also plans to broaden its shareholder base, particularly in the United States, to support its future growth.